Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia

Shilpa Paul, Adam J. Dipippo, Farhad Ravandi, Tapan M. Kadia

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

FLT3 mutations, characterized by an internal-tandem duplication or missense mutations in the tyrosine kinase domain, are observed in a third of patients with newly diagnosed acute myeloid leukemia. FLT3-ITD mutations are associated with high relapse rates and short overall survival with conventional chemotherapy. Several tyrosine kinase inhibitors targeting FLT3 have been developed in an effort to improve survival and therapeutic options. This review focuses on quizartinib, a second-generation FLT3 inhibitor that has demonstrated efficacy and safety as a single agent and in combination with chemotherapy. We discuss its clinical development as well as its place in the treatment of FLT3-mutated acute myeloid leukemia among the other FLT3 inhibtors currently available and its mechanisms of resistance.

Original languageEnglish (US)
Pages (from-to)3885-3894
Number of pages10
JournalFuture Oncology
Volume15
Issue number34
DOIs
StatePublished - 2019

Keywords

  • FLT3 mutation
  • FLT3-ITD AML
  • acute myeloid leukemia
  • quizartinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this